Trial Profile
Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 Following 8 Weeks Oral Administration of YHD001 in Patients With Partially Controlled Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2014
Price :
$35
*
At a glance
- Drugs YHD 001 (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Yuhan
- 09 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 25 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.